



Washington State Health Care Authority  
**Prescription Drug Program**

626 8<sup>th</sup> Ave SE, Olympia, WA 98501 • 206-521-2029

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

12/28/2020

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective April 1, 2021:

CGRP Inhibitors reviewed 8/19/2020		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
fremanezumab	Ajovy <sup>®</sup> syringe	Not participating	Yes
Fremanezumab-VFRM	Ajovy <sup>®</sup> auto-injection	Not participating	Yes
The effect of this recommendation is to make Ajovy <sup>®</sup> preferred, and Emgality <sup>®</sup> non-preferred on the WA PDL.			

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at [leta.evaskus@hca.wa.gov](mailto:leta.evaskus@hca.wa.gov).

Sincerely,

Donna Sullivan  
Chief Pharmacy Officer  
Clinical Quality and Care Transformation  
Washington State Health Care Authority